Active surveillance for low-risk prostate cancer
Critical Reviews in Oncology / Hematology , Volume 85 - Issue 3 p. 295- 302
Active surveillance (AS) is an important management strategy for men diagnosed with low-risk prostate cancer (PCa). The need for AS is increasing due to the awareness that many PCa are identified that show a low growth potential and therefore are likely to remain clinically asymptomatic during the lifetime of an individual. Currently there is no good method to prevent the overdiagnosis of indolent cancers upfront. During the last decade, several studies on AS around the world have made observations that feed the discussion on how to select and monitor these patients, how to proceed with the research to develop a better and more precise clinical definition of indolent cancers and how to manage men under AS clinically. Furthermore, patients' perspectives have become clearer, and quality of life studies give direction to the practical approach and care for patients and partners. This paper reflects the consensus on the state of the art and the future direction of AS, based on the Inside Track Conference " Active Surveillance for low risk prostate cancer" (Chairmen: C.H. Bangma, NL, and L. Klotz, CA; Co-Chairmen: L.J. Denis, BE, and C. Parker, UK; Scientific Coordinators: M. J. Roobol, NL, and E.W. Steyerberg, NL), organized by the European School of Oncology in collaboration with Europa Uomo in Rotterdam, the Netherlands in January 2012. Topics for discussion were the optimisation of patient selection based on indolent disease definition, the incorporation of therapeutic agents into AS programs, the optimisation of patient care, and the application of emerging technologies and biomarkers.
|Active surveillance, Biomarkers, Imaging, Nomograms, Overdiagnosis, Prostate cancer, Screening|
|Critical Reviews in Oncology / Hematology|
|Organisation||Department of Pathology|
Bangma, C.H, Bul, M, van der Kwast, Th.H, Pickles, T, Korfage, I.J, Hoeks, C, … Valdagni, R. (2013). Active surveillance for low-risk prostate cancer. Critical Reviews in Oncology / Hematology (Vol. 85, pp. 295–302). doi:10.1016/j.critrevonc.2012.07.005